Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18613639 | 1.00 | KMT2A (0.43) | KMT2AALDH1A1MEN1MAPTKDM4E | |
| SCHEMBL3648459 | 0.87 | CSNK2A2 (0.45) | KMT2AALDH1A1MEN1KDM4EHPGD | |
| SCHEMBL3648457 | 0.87 | CSNK2A2 (0.45) | KMT2AALDH1A1MEN1KDM4EHPGD | |
| SCHEMBL29602518 | 0.86 | DPP4 (0.44) | NPC1RAB9AFDPSCCNCCDK8 | |
| SCHEMBL2543479 | 0.86 | DPP4 (0.44) | NPC1RAB9AFDPSCCNCCDK8 | |
| SCHEMBL3931438 | 0.82 | KMT2A (0.43) | KMT2AALDH1A1MEN1MAPTKDM4E | |
| SCHEMBL3930401 | 0.82 | KMT2A (0.43) | KMT2AALDH1A1MEN1MAPTKDM4E | |
| SCHEMBL29551120 | 0.82 | NNMT (0.50) | KMT2AALDH1A1MEN1MAPTKDM4E | |
| SCHEMBL20439701 | 0.82 | NNMT (0.50) | KMT2AALDH1A1MEN1MAPTKDM4E | |
| SCHEMBL3785658 | 0.77 | MAPT (0.46) | KMT2AALDH1A1MEN1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267820-B2 | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | JUBILANT BIOSYS LIMITED (IN) | 2022-03-08 | — | — | US | disclosed |
| CN-108137588-B | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | 朱比兰特生物系统有限公司 | 2021-06-18 | — | — | CN | disclosed |
| EP-3347356-B1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LTD (IN) | 2021-03-24 | — | — | EP | disclosed |
| US-20200339595-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2020-10-29 | — | — | US | disclosed |
| US-10689395-B2 | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | JUBILANT BIOSYS LIMITED (IN) | 2020-06-23 | — | — | US | disclosed |
| US-20180237453-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2018-08-23 | — | — | US | disclosed |
| EP-3347356-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | Jubilant Biosys Limited (IN) | 2018-07-18 | — | — | EP | disclosed |
| WO-2017042834-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339595-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | BRD4, BET1, BRD2 | KMT2A 490/4885ALDH1A1 4453/4885MEN1 2240/4885 |
| US-20180237453-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | BRD4, BET1, BICRA | KMT2A 433/4885ALDH1A1 4337/4885MEN1 2279/4885 |
| US-10689395-B2 | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | BRD4, BET1, BICRA | KMT2A 433/4885ALDH1A1 4337/4885MEN1 2279/4885 |
| US-11267820-B2 | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | BRD4, BET1, BRD2 | KMT2A 490/4885ALDH1A1 4453/4885MEN1 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.